Stockscreener 앱 받기
2.34
1.27%
-0.03
시간 외 거래:
2.38
0.04
+1.71%
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
Daré Bioscience Receives NIH Funding Award Notice to - GlobeNewswire
Dare Bioscience Inc (DARE) Stock Price, Quote, News & History - Benzinga
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience outlines liquidity and revenue plans in Q1 2026 - Investing.com
Dare Bioscience, Inc.Common Stock (NQ: DARE - The Chronicle-Journal
Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - Sahm
Dare Bioscience (DARE) Launches Phase 2 Study for DARE-HPV Treat - GuruFocus
Daré Bioscience Completes Regulation A Investor Unit Offering - TipRanks
Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com South Africa
Dare Bioscience completes closing of Regulation A equity offering - Investing.com
Daré Bioscience (NASDAQ: DARE) issues 50,000 preferred unit package - Stock Titan
Dare Bioscience Q3 2025 Earnings Preview - MSN
Daré Bioscience begins phase 2 trial for HPV treatment By Investing.com - Investing.com South Africa
Daré Bioscience initiates phase 2 study of Dare-HPV - marketscreener.com
Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv - TradingView
Daré Bioscience begins phase 2 trial for HPV treatment - Investing.com
Daré Bioscience Initiates Phase 2 Study for DARE-HPV, Potential First Pharmacologic Treatment for High-Risk HPV Infection - Quiver Quantitative
6M women get high-risk HPV yearly; new trial tests first potential drug - Stock Titan
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Q1 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Str - GuruFocus
Daré Bioscience Releases Q1 2026 Financial Results - AlphaStreet
Daré Bioscience (DARE) Reports Positive Developments and Financi - GuruFocus
Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June - MSN
Dare Bioscience (DARE) Q1 2026: EPS -$0.20 vs -$0.27 est (beat); - GuruFocus
Earnings call transcript: Dare Bioscience sees stock uptick, product launch By Investing.com - Investing.com Nigeria
Earnings call transcript: Dare Bioscience sees stock uptick, product launch - Investing.com
Dare Bioscience Q1 2026 Earnings Call: Complete Transcript - Benzinga
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dare Bioscience Revenue From DARE to RECLAIM Is Targeted to Begin in 2027 >DARE - Moomoo
Daré Bioscience (NASDAQ:DARE) Q1 2026 Results Show Mixed Bag with Revenue Miss but EPS Beat and Upcoming Product Launches - ChartMill
DARE BIOSCIENCE ($DARE) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Dare Bioscience | 10-Q: Q1 2026 Earnings Report - Moomoo
Daré Bioscience (NASDAQ: DARE) narrows Q1 loss but flags going concern risk - Stock Titan
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Daré Bioscience (NASDAQ: DARE) details Q1 loss and 2026–27 revenue milestones - Stock Titan
Press Release: Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Dare Bioscience Q1 2026 earnings preview - MSN
12 Health Care Stocks Moving In Thursday's After-Market Session - Sahm
Why is nano-cap Dare Bioscience stock trading higher on Tuesday? - MSN
Dare Bioscience Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday? - Benzinga
Daré Bioscience reports interim phase 3 data for Ovaprene - Investing.com India
Dare Bioscience IncNo Serious Adverse Even - Moomoo
0.98%
0.12%
자본화:
|
볼륨(24시간):